Track topics on Twitter Track topics that are important to you
AlphaVax is developing a new vaccine technology with broad applications against infectious disease, cancer and biodefense threats which has the potential to redefine vaccines and the role they play in medicine.
AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines, which have shown excellent protection in multiple models for infectious disease and cancer. Since 1998, the company has raised more than $110 million, with 75% coming from corporate partner and grant funding, and has advanced the alphavaccine platform system from the academic laboratory to human clinical trials, establishing the technical, regulatory, and manufacturing foundation for commercializing alphavaccines.
The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical data from the first alphavaccine human trials have confirmed safety and immunological activity in man, and additional trials for other diseases are expected to begin in 2006.
The vaccine market is primed for dramatic growth and the AlphaVax vaccine technology will play a key role in an expanding industry expected to reach $20 billion by 2015.
We are located in Research Triangle Park, North Carolina and employ over 65 staff in a state-of-the-art, 30,000-square-foot research and development facility that includes Bio-Safety Level 2 and 3 (BSL-2/3) laboratories.
P.O. Box 110307
Research Triangle Park
United States of America
Botulism Treatment Market: By Type Infant and Adult Foodborne botulism, wound botulism and others; By Drug Type Antitoxin and Antibiotics; By Geography Forecast 2016 2021 [Updated: 22012016] Prices from USD $5250
Botulism is a type of poisoning or infection caused by certain bacteria on the preserved food material. It is a rare but very serious illness which disseminates through food coming in contact with con...
AlphaVax, Inc. is a North Carolina-based, clinical-stage company that uses a proprietary alphavirus vector platform technology that has proven to be highly flexible and immunogenic, and allows the sam...
AlphaVax is developing a new vaccine technology with broad applications against infectious disease, cancer and biodefense threats which has the potential to redefine vaccines and the role they play in...
We have published hundreds of AlphaVax, Inc news stories on BioPortfolio along with dozens of AlphaVax, Inc Clinical Trials and PubMed Articles about AlphaVax, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AlphaVax, Inc Companies in our database. You can also find out about relevant AlphaVax, Inc Drugs and Medications on this site too.
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...